Tempus AI, Inc (TEM)
Market Cap | 5.01B |
Revenue (ttm) | 640.44M |
Net Income (ttm) | -800.71M |
Shares Out | 157.45M |
EPS (ttm) | -8.52 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,997,652 |
Open | 33.10 |
Previous Close | 32.34 |
Day's Range | 31.67 - 34.62 |
52-Week Range | 22.89 - 79.49 |
Beta | n/a |
Analysts | Buy |
Price Target | 57.20 (+79.71%) |
Earnings Date | Feb 17, 2025 |
About TEM
Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to ph... [Read more]
Financial Performance
In 2023, Tempus AI's revenue was $531.82 million, an increase of 65.85% compared to the previous year's $320.67 million. Losses were -$265.96 million, -20.35% less than in 2022.
Financial numbers in USD Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $57.2, which is an increase of 79.71% from the latest price.
News
Tempus AI: Disappointing Q4 Preliminary Results, But Bullish Fundamental Update
Tempus AI is a leading player in healthcare AI, aiming to deliver personalized treatment suggestions through its proprietary data model. Preliminary Q4 results and 2025 guidance show mixed performance...
Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative...
Tempus Announces Its First-Ever, Whole-Genome Sequencing Assay, xH
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its f...
Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited ...
Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, ...
Tempus to Present at 43rd Annual J.P. Morgan Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the 43rd Annual J.P. Morgan...
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
It's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling from the aftermath. According to a CNBC analysis of 39 public digital health com...
Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions
CHICAGO--(BUSINESS WIRE)--Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network ...
Tempus AI: Recent Weakness Presents Gift Ahead Of The Holidays
Tempus AI has strong long-term potential in healthcare technology, despite recent stock volatility due to lock-up period expiration and insider selling. The company's innovative "Intelligent Diagnosti...
New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by...
Personalis and Tempus Expand Collaboration to Biopharma
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed...
Tempus AI: Why I'm Buying This AI Stock
Tempus AI's strategic acquisitions and partnerships, including Ambry Genetics and a JV with SoftBank, bolster its growth and competitive edge in AI health tech. The revenue growth and gross margins fo...
Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annu...
The Big 3: CRWD, CVNA, TEM
@ProsperTradingAcademy's Charles Moon is bullish on all of today's Big 3. He points to Crowdstrike's (CRWD) recovery and Carvana (CVNA) coiling to the upside as positive markers but warns of volatilit...
Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation
Tempus AI, Inc. founded in 2015, leverages AI for precision medicine, showing strong growth since its June 2024 listing, presenting a buying opportunity. The company boasts a vast clinical and molecul...
Tempus Molecular Profiling Integration Now Available Through Flatiron's OncoEMR®
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron...
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Acti...
Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript
Tempus AI, Inc. (NASDAQ:TEM) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Liz Krutoholow – Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer...
Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted fo...
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immu...
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...
Tempus to Report Third Quarter 2024 Financial Results on November 4
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday,...
Tempus and Northwestern Medicine Announce Collaboration to Bring Practical Application of AI to Healthcare
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, and Northwestern Medicine, Chicago's premier integrated academic health system, today announced a collabor...
Tempus: Attempting To Lead The AI Revolution In Healthcare
Tempus AI, Inc, a healthcare technology company, has shown DECENT gains since its listing in June, outperforming the Nasdaq and AI-themed stock portfolios. TEM aims to leverage AI and ML and revolutio...
Tempus to Report Third Quarter 2024 Financial Results on November 7
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursda...